EP1517702A4 - MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL - Google Patents

MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL

Info

Publication number
EP1517702A4
EP1517702A4 EP03709214A EP03709214A EP1517702A4 EP 1517702 A4 EP1517702 A4 EP 1517702A4 EP 03709214 A EP03709214 A EP 03709214A EP 03709214 A EP03709214 A EP 03709214A EP 1517702 A4 EP1517702 A4 EP 1517702A4
Authority
EP
European Patent Office
Prior art keywords
terminal cysteine
particles stabilized
hbc chimer
chimer particles
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03709214A
Other languages
English (en)
French (fr)
Other versions
EP1517702A2 (de
Inventor
Ashley J Birkett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apovia Inc
Original Assignee
Apovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/082,014 external-priority patent/US20030185858A1/en
Priority claimed from US10/080,299 external-priority patent/US20030175863A1/en
Priority claimed from US10/274,616 external-priority patent/US20030202982A1/en
Application filed by Apovia Inc filed Critical Apovia Inc
Publication of EP1517702A2 publication Critical patent/EP1517702A2/de
Publication of EP1517702A4 publication Critical patent/EP1517702A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP03709214A 2002-02-21 2003-02-21 MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL Withdrawn EP1517702A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US82014 1998-05-20
US10/082,014 US20030185858A1 (en) 2001-08-15 2002-02-21 Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US10/080,299 US20030175863A1 (en) 2001-08-15 2002-02-21 Influenza immunogen and vaccine
US80299 2002-02-21
US10/274,616 US20030202982A1 (en) 2001-08-15 2002-10-21 Influenza immunogen and vaccine
US274616 2002-10-21
PCT/US2003/005196 WO2003102165A2 (en) 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Publications (2)

Publication Number Publication Date
EP1517702A2 EP1517702A2 (de) 2005-03-30
EP1517702A4 true EP1517702A4 (de) 2006-05-03

Family

ID=29715970

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03709214A Withdrawn EP1517702A4 (de) 2002-02-21 2003-02-21 MIT EINEM N-TERMINALEN CYSTEIN STABILISIERTE IMMUNOGENE HBc-CHIMÄRE-PARTIKEL

Country Status (3)

Country Link
EP (1) EP1517702A4 (de)
AU (1) AU2003213168A1 (de)
WO (1) WO2003102165A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
RU2009105099A (ru) 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
KR20090096414A (ko) 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2680883B1 (de) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9-impfstoff
CN106279379B (zh) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 一种免疫原HM4-M2e及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
WO1999057289A2 (en) * 1998-05-04 1999-11-11 Michigan State University INHIBIN-HBc FUSION PROTEIN
WO2002014478A2 (en) * 2000-08-16 2002-02-21 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
WO1999057289A2 (en) * 1998-05-04 1999-11-11 Michigan State University INHIBIN-HBc FUSION PROTEIN
WO2002014478A2 (en) * 2000-08-16 2002-02-21 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KRATZ P A ET AL: "NATIVE DISPLAY OF COMPLETE FOREIGN PROTEIN DOMAINS ON THE SURFACE OF HEPATITIS B VIRUS CAPSIDS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 96, 1999, pages 1915 - 1920, XP000910194, ISSN: 0027-8424 *
SEIFER M ET AL: "Stability governs the apparent expression of particulate hepatitis e antigen by mutant hepatitis B virus core particles", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 196, no. 1, September 1993 (1993-09-01), pages 70 - 78, XP002961918, ISSN: 0042-6822 *
ULRICH R ET AL: "CORE PARTICLES OF HEPATITIS B VIRUS AS CARRIER FOR FOREIGN EPITOPES", ADVANCES IN VIRUS RESEARCH, SAN DIEGO, CA, US, vol. 50, 1998, pages 141 - 182, XP000856161 *
ZHOU S ET AL: "Cys residues of the hepatitis B virus capsid protein are not essential for the assembly of viral core particles but can influence their stability", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 9, September 1992 (1992-09-01), pages 5393 - 5398, XP002961917, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2003102165A2 (en) 2003-12-11
EP1517702A2 (de) 2005-03-30
AU2003213168A1 (en) 2003-12-19
WO2003102165A3 (en) 2005-01-06
AU2003213168A8 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
AU2003293294A8 (en) Uv-stabilised particles
EP1492049A4 (de) Erzeugung von gesichts-metadaten
HRP20041200A2 (en) Acidic insulin preparations with improved stability
IL172059A0 (en) Stabilized radiopharmaceutical compositions and methods for the preparation thereof
AU2003301769A8 (en) Stabilized semiconductor nanocrystals
SG106158A1 (en) Screw-on for timepiece
HK1137439A1 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
AU2003225901A8 (en) Stabilized inorganic particles
EP1559433A4 (de) Stabilisierte zusammensetzung
AU2003213168A8 (en) Immunogenic hbc chimer particles stabilized with an n-terminal cysteine
IL168106A0 (en) Stabilized, solid-state polypeptide particles
GB2392424B (en) Fuel sender assembly
AU2003206862A1 (en) Hepatitis b vaccines
GB2390234B (en) Fuel sender assembly
AU2003254483A8 (en) Fuel composition
AU2003215395A8 (en) Stabilized hbc chimer particles having meningoccocal immunogens
TW547897U (en) Housing with separated carrying seat
AU2003303222A8 (en) Mutant proteins with increased secretion
AU2003249282A1 (en) Glanders/meliodosis vaccines
GB0201382D0 (en) Virus-like particles
ZA200605668B (en) Fused pyrrolocarbazoles and methods for the preparation thereof
PL372202A1 (en) Modified byrodin 1 with reduced immunogenicity
GB2407171B (en) Particle collector
GB0208414D0 (en) The overlock
GB0326887D0 (en) Improved thermosetting powder

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040921

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20060320

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/385 20060101ALI20060315BHEP

Ipc: A61K 39/29 20060101ALI20060315BHEP

Ipc: C12Q 1/70 20060101AFI20060315BHEP

17Q First examination report despatched

Effective date: 20091130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130216